Претраживање
Приказ резултата 1-2 од 2
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
(Amer Soc Hematology, Washington, 2019)
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative ...
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
(Amer Soc Hematology, Washington, 2008)
Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the ...